Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial

Darren K. McGuire, Bernard Zinman, Silvio E. Inzucchi, Christoph Wanner, David Fitchett, Stefan D. Anker, Stuart Pocock, Stefan Kaspers, Jyothis T. George, Maximilian von Eynatten, Odd Erik Johansen, Waheed Jamal, Michaela Mattheus, Ulrich Elsasser, Stefan Hantel, Søren S. Lund